Anders Bjartell Selected Research

galiellalactone

1/2020	STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population.
10/2019	The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors.
3/2016	The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
6/2014	Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells.
1/2011	Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells.
2/2008	Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anders Bjartell Research Topics

Disease

146	Prostatic Neoplasms (Prostate Cancer) 10/2022 - 05/2002
63	Neoplasms (Cancer) 04/2022 - 05/2002
23	Neoplasm Metastasis (Metastasis) 01/2021 - 01/2005
12	Disease Progression 01/2020 - 01/2009
7	Carcinogenesis 01/2014 - 02/2004
6	Margins of Excision 09/2021 - 01/2009
6	Carcinoma (Carcinomatosis) 02/2016 - 09/2002
4	Urinary Incontinence 01/2017 - 01/2015
4	Colorectal Neoplasms (Colorectal Cancer) 09/2011 - 09/2010
3	Lymphatic Metastasis 08/2021 - 07/2008
3	Adenocarcinoma 01/2019 - 05/2012
3	Breast Neoplasms (Breast Cancer) 11/2017 - 01/2005
2	COVID-19 01/2022 - 03/2021
2	Fatigue 10/2021 - 11/2019
2	Pain (Aches) 10/2021 - 11/2019
2	Erectile Dysfunction 01/2017 - 01/2015
2	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 12/2010 - 09/2002
2	Inflammation (Inflammations) 12/2007 - 09/2004
2	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 09/2005 - 02/2004
1	Lower Urinary Tract Symptoms 04/2021
1	Virus Diseases (Viral Diseases) 03/2021

Drug/Important Bio-Agent (IBA)

31	Biomarkers (Surrogate Marker)IBA 02/2021 - 08/2009
24	Prostate-Specific Antigen (Semenogelase)IBA 07/2022 - 12/2002
22	Proteins (Proteins, Gene)FDA Link 11/2019 - 10/2003
21	AndrogensIBA 01/2022 - 10/2003
13	Messenger RNA (mRNA)IBA 11/2019 - 05/2002
12	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 11/2009
8	Hormones (Hormone)IBA 04/2022 - 02/2008
7	AntigensIBA 10/2022 - 12/2010
7	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 04/2022 - 02/2008
7	enzalutamideIBA 01/2022 - 02/2015
6	Kallikreins (Kallikrein)IBA 11/2021 - 02/2011
6	galiellalactoneIBA 01/2020 - 02/2008
6	Kazal Pancreatic Trypsin InhibitorIBA 01/2019 - 10/2005
6	Peptide Hydrolases (Proteases)FDA Link 08/2015 - 11/2003
5	Transcription Factors (Transcription Factor)IBA 10/2019 - 07/2011
4	Docetaxel (Taxotere)FDA Link 01/2022 - 11/2019
4	apalutamideIBA 10/2021 - 01/2019
4	Peptides (Polypeptides)IBA 01/2017 - 04/2006
4	Biological ProductsIBA 04/2015 - 12/2010
4	MicroRNAs (MicroRNA)IBA 06/2013 - 12/2010
4	Cyclin A1IBA 07/2008 - 02/2004
3	Testosterone (Sustanon)FDA Link 01/2022 - 12/2017
3	Abiraterone AcetateIBA 01/2022 - 12/2016
3	abirateroneIBA 01/2022 - 02/2015
3	LigandsIBA 01/2022 - 01/2005
3	Interleukin-6 (Interleukin 6)IBA 10/2019 - 04/2008
3	ProteomeIBA 01/2019 - 01/2015
3	RNA (Ribonucleic Acid)IBA 01/2015 - 05/2009
3	Monoclonal AntibodiesIBA 12/2014 - 05/2012
3	Matrix Metalloproteinases (MMPs)IBA 11/2009 - 06/2005
2	Androgen Antagonists (Antiandrogens)IBA 01/2022 - 01/2022
2	Pharmaceutical PreparationsIBA 11/2021 - 01/2016
2	Interleukin-10 (Interleukin 10)IBA 11/2021 - 10/2019
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 01/2016
2	CytokinesIBA 10/2019 - 09/2004
2	ChromatinIBA 01/2019 - 10/2013
2	Serum Response FactorIBA 01/2018 - 11/2015
2	ORALIT (ORS)IBA 07/2017 - 01/2014
2	EpitopesIBA 01/2017 - 05/2012
2	darolutamideIBA 12/2016 - 02/2015
2	SteroidsIBA 01/2016 - 04/2006
2	Formaldehyde (Formol)FDA Link 01/2016 - 06/2013
2	ParaffinIBA 01/2016 - 06/2013
2	Small Interfering RNA (siRNA)IBA 01/2016 - 07/2008
2	Wnt-5a ProteinIBA 08/2012 - 01/2011
2	Trypsin InhibitorsIBA 08/2011 - 09/2010
2	Phosphotransferases (Kinase)IBA 07/2011 - 01/2005
2	Cystatin CIBA 11/2009 - 07/2006
2	Serine Proteases (Serine Protease)IBA 08/2009 - 06/2005
2	Metalloproteases (Metalloproteinases)IBA 07/2008 - 02/2008
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2008 - 09/2005
2	ChemokinesIBA 12/2007 - 09/2004
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 04/2006 - 05/2002
2	Somatostatin Receptors (Somatostatin Receptor)IBA 09/2002 - 05/2002
1	hydroxyflutamideIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	bicalutamide (Casodex)FDA LinkGeneric 01/2022
1	Therapeutic UsesIBA 01/2022
1	fluorocholineIBA 08/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 07/2021
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 07/2021
1	olaparibIBA 07/2021
1	rucaparibIBA 07/2021
1	5-alpha Reductase InhibitorsIBA 04/2021
1	RadiopharmaceuticalsIBA 03/2021

Therapy/Procedure

37	Prostatectomy (Retropubic Prostatectomy) 06/2022 - 05/2002
33	Castration 01/2022 - 10/2009
27	Therapeutics 10/2022 - 02/2008
7	Radiotherapy 01/2022 - 06/2011
4	Drug Therapy (Chemotherapy) 01/2021 - 12/2013
3	Robotic Surgical Procedures 08/2021 - 04/2015
3	Duration of Therapy 01/2020 - 10/2019
2	Lymph Node Excision (Lymph Node Dissection) 08/2021 - 01/2015
2	Precision Medicine 02/2021 - 01/2019
2	Aftercare (After-Treatment) 08/2016 - 04/2006
1	Critical Care (Surgical Intensive Care) 01/2022
1	Immunotherapy 11/2021
1	Artificial Respiration (Mechanical Ventilation) 03/2021
1	Sutures (Suture) 01/2021